Oracle has unveiled version 3.0 of OutcomeLogix to help research organizations collect data on late-stage studies of diverse patient populations.
Oracle Health Sciences has introduced OutcomeLogix On Demand 3.0, a Web-based application that enables life science companies and contract research organizations to collect data on the outcome of various therapy treatments in late-stage trials.
The company announced the product at the Oracle Health Sciences User Group (OHSUG) annual conference in Toronto on Oct. 17. Formed in 1995, OHSUG aims to promote the exchange of health care data using Oracle Health Sciences products.
OutcomeLogix will pull data from health care providers and patients on late-stage studies to provide a complete picture of therapy outcomes, Oracle reports.
"OutcomeLogix is a Web-based data-collection system designed specifically for the expanding needs of late-phase and outcome-based research worldwide," Scott Dixon, lead strategist for Oracle's late phase and direct-to-patient solutions, said in a company video.
"Oracle Health Sciences OutcomeLogix On Demand 3.0 delivers a flexible solution that is not only cost-effective to deploy and maintain, but is also easy for health care providers and patients to navigate," Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences, said in a statement.
Users can enter data in OutcomeLogix on a desktop, laptop, tablet and mobile device in the cloud.
The application features ePro, a tool that walks patients, observers and caretakers through entering clinical trial data in questionnaires and surveys. Users enter data through a Secure Sockets Layer log-in.
Meanwhile, a built-in tool called SleepLogix provides an illustrated view of time points that patients enter in a way similar to those used by sleep clinics.
OutcomeLogix is a scalable platform that can adapt to various geographic and cultural boundaries as well as patient populations, Dixon said. Oracle intends for this scalability platform to support data collection for patients decades into the future, the company reports.
"Study sponsors and CROs, responding to regulatory mandates for increased post-approval surveillance and the growing need for patient-reported outcomes, are seeking technology solutions from a global, trusted provider to accommodate data collection across vast patient populations," de Crescenzo said.
In designing OutcomeLogix, Oracle wanted to help health care professionals and researchers increase health outcomes as well as improve the safety of health care applications and the long-term efficacy in treatment.
"Our overall goal for version 3.0 was to enable CROs and sponsors to design and launch new projects more efficiently," Dixon said.
OutcomeLogix runs in the Oracle Health Sciences Cloud, a Web-based infrastructure that allows health care researchers to deploy scalable applications and manage trial data used by life science organizations, CROs and academic medical facilities.
"It supports the increasingly networked environment for research and development, where data must be effectively shared and managed securely across multiple organizations, including life sciences companies, academic medical centers, contract research organizations and regulators in government worldwide," de Crescenzo said in a company video.
Through its Health Sciences Cloud, Oracle aims to speed up IT deployments and reduce the IT infrastructure needed to run health care applications.
Other Oracle cloud applications unveiled recently include the Health Sciences Trial Center, which provides a single view of multiple trials across drug research and development trial systems.
Brian T. Horowitz is a freelance technology and health writer as well as a copy editor. Brian has worked on the tech beat since 1996 and covered health care IT and rugged mobile computing for eWEEK since 2010. He has contributed to more than 20 publications, including Computer Shopper, Fast Company, FOXNews.com, More, NYSE Magazine, Parents, ScientificAmerican.com, USA Weekend and Womansday.com, as well as other consumer and trade publications. Brian holds a B.A. from Hofstra University in New York.